# Aerie licenses DSM's bioerodible implant technology for ophthalmic use for $15M

Aerie Pharmaceuticals licensed DSM's bioerodible implant technology for ophthalmic applications in a deal valued at $15 million.

- Type: Contract
- Announced: 2018-08-03
- Value: $15.0M
- Status: announced
- Products: bioerodible implant technology for ophthalmic use
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Aerie Pharmaceuticals](https://endata.com/companies/21333.md)
- [DSM](https://endata.com/companies/25138.md) (partner)

## Sources

- [market-scope.com](https://www.market-scope.com/pages/news/115/aerie-licenses-dsms-bioerodible-implant-technology-for-ophthalmic-use-for-15-million), 2018-08-03: "Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.